On August 2, 2023, Forte Biosciences, Inc. filed a preliminary proxy statement soliciting proxies and urged the shareholders to vote against a shareholder proposal, requesting that the Board of Directors of the Company take all steps necessary to terminate without delay the Preferred Stock Rights Agreement, dated as of July 12, 2022, as amended on June 26, 2023, submitted by Funicular Funds, LP at the Company?s annual shareholders meeting scheduled to be held on September 19, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.651 USD | +3.33% | -12.62% | -20.77% |
13/05 | Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.77% | 2.29Cr | |
+8.93% | 11TCr | |
+11.48% | 10TCr | |
-12.78% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-3.24% | 1.79TCr | |
+7.97% | 1.43TCr | |
+34.49% | 1.25TCr |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Funicular Funds Submits a Shareholder Proposal to Forte Biosciences